Daily Biotech Movers — 2026-08-10: A Tale of Two -90% Clinical Failures on a Flat Tape

Monday, August 10, 2026 was the tape’s quietest center and its loudest tails at the same time. The center went nowhere: 286 names finished higher and 284 lower — a 1.0-to-1 advance ratio, essentially a coin flip — with a median move of +0.04% and a mean of -0.21% across 570 directional moves among 581 tracked companies. But the tails were the most violent of the month: two companies lost roughly 90% in a single session — Sionna Therapeutics (-91.18%) on a failed cystic fibrosis trial and Tenax Therapeutics (-89.77%) on a failed Phase 3 heart-failure trial — while the index trio told a defensive-rotation story: XLV +1.67%, IBB +1.17%, XBI +0.42%, SPY -0.03%. The standard deviation of 7.47% — the widest since mid-June — with a median near zero is the fingerprint of a day where binary clinical data, not beta, set the price. 108 names were anomaly-flagged (a move of at least 5% or volume at least 2x normal), and 92 of those moved at least 5% on price.

The leaderboard is a study in asymmetric risk. On the upside, the winners were balance-sheet and pipeline stories: Aligos Therapeutics (+36.85%) extended a licensing-driven re-rating from its August 6 Q2 report, Tenon Medical (+31.95%) bounced mechanically on its first session after a 1-for-35 reverse split, and Innate Pharma (+28.32%) printed the day’s heaviest volume — 27x normal — on a Phase 1 enrollment milestone and a Sobi partnership advancing lacutamab toward Phase 3. On the downside, the two -90% prints are the day’s defining events: Sionna scrapped its cystic fibrosis program after the Phase 2a miss and closed below its reported gross cash, and Tenax’s Phase 3 LEVEL trial of oral levosimendan missed its 6-minute-walk primary endpoint, unwinding a thesis that analysts had rated as high as $50. The pattern is brutal and simple: on a flat tape, every remaining dollar of biotech risk is being sorted by binary data events — and the downside tail of that distribution is far heavier than the upside.

The Distribution

Measure	August 10 reading
Tracked / priced	581
Directional moves	570
Up / down	286 / 284
Mean / median	-0.21% / +0.04%
Standard deviation	7.47%
Anomaly-flagged	108
Price moves of at least 5%	92

Breadth was dead flat at 1.0 advancers per decliner — the most balanced tape of the earnings season — yet the standard deviation of 7.47% is the widest dispersion since mid-June. That combination (median ~0, tails enormous) is the statistical signature of an event-driven day with no sector-level thesis: the two -90% crashes alone account for more than two points of the dispersion. The index read confirms the rotation was defensive: XLV (+1.67%) led, IBB (+1.17%) and XBI (+0.42%) followed, and SPY was flat (-0.03%). Capital moved within healthcare toward large-cap quality, and the small-cap biotech universe — where the binary events live — sorted itself name by name.

The 6 Classes of Mover Signal

On August 10, three of the six top movers are Class 2 single-stock data events (two fatal, one milestone), one is Class 1 mechanical, one is a Class 2 fundamental continuation, and the sector read is Class 4 defensive — a clinical-failure day with a corporate-action headline on top.

1. Halt-release or reverse-split-adjacent. TNON (Tenon Medical, +31.95% at $6.05) is the day’s lone Class 1 print: the 1-for-35 reverse stock split became effective at 12:01 a.m. ET on August 10 (RTTNews — Tenon Medical Implements 1-for-35 Reverse Stock Split; Nasdaq Trader — Equity Corporate Actions Alert #2026-554; Access Newswire — Tenon Medical announces 1:35 reverse stock split). Friday’s $0.13 close splits to a $4.55 reference; the stock opened post-split and closed 31.95% above that reference on 3.24x volume with five-day momentum of -9.0% — a post-split bounce with no fresh business news. The same name that slid 22% into the split on Friday is now the day’s second-biggest gainer on split-adjusted terms: pure corporate-action mechanics on the Catamaran SI-joint fusion franchise.

2. Single-stock clinical or regulatory event. The day’s center of gravity, and it ran in both directions. SION (Sionna Therapeutics, -91.18%) and TENX (Tenax Therapeutics, -89.77%) are fatal Class 2 reads — a scrapped Phase 2a CF program and a missed Phase 3 heart-failure endpoint (details below). IPHA (Innate Pharma, +28.32%) is the positive leg: enrollment completed in the dose-escalation phase of the IPH4502 Phase 1 trial (76 advanced solid-tumor patients, early responses, limited blood-related toxicity) plus a Sobi partnership advancing lacutamab toward Phase 3 (StocksToTrade; Innate Pharma IR). When the only clean catalysts on a flat day are clinical, the market is telling you it has stopped paying for beta and will only pay for data.

3. Buyout or strategic capital. No top-six print is a pure Class 3 event today. The closest analog is IPHA’s Sobi partnership — strategic capital funding a Phase 3 path — and ALGS’s $25 million China licensing deal, which has a strategic-capital flavor even though it booked as revenue. Neither is a buyout; both are capital infusions that de-risked a balance sheet.

4. Sector rotation. The sector read is defensive with one mechanical outlier. Leaders: Devices — Implants (+4.80% across 10 — but with a +3.14% median, meaning real strength beyond TNON’s print), RNA, Peptide & Gene Therapy (+1.83% across 26), Genetics & Genomics (+1.61% across 7), Antibodies (+1.39% across 41). Laggards: Drug Delivery/Formulation (-3.02% across 31), Generic Drugs (-1.82% across 5), Non-Pharmaceutical Biotech (-1.69% across 20), Small Molecule Pharma (-1.59% across 151). The index trio (XLV +1.67% > IBB +1.17% > XBI +0.42% > SPY -0.03%) shows capital rotating into large-cap healthcare and out of the small-cap, high-beta end of the sector — the opposite of Friday’s risk-on biotech bid.

5. Sell-the-news / prior-cycle profit-taking. ALGS (Aligos Therapeutics, +36.85%) is the closest Class 5-adjacent print, but its framing is continuation, not unwind: five-day momentum of +66.3% against a +36.85% session means the market has been re-rating the name since the August 6 Q2 report — Monday is the follow-through leg of the licensing story, not a fresh catalyst. Continuation leg of a Class 2 fundamental event — flagged as such, not a fresh same-day catalyst. No top-six loser carries a prior-cycle signature today; both crashes are fresh same-day disclosures.

6. Stealth accumulation / distribution. COCP (Cocrystal Pharma) traded 4.26x normal volume on +1.89% with 5d of +14.9% (accumulation-leaning), ELAN (Elanco Animal Health) 3.28x on +0.72% with 5d of -13.4% (distribution-leaning), and CVRX (CVRx) 3.27x on -0.84% with 5d of -56.9% — the continued unwinding of last week’s -60% guidance-crash in heavy, unresolved tape. All three are flow signals to resolve over the next one to three sessions.

Top 3 Winners — What Drove Them

ALGS — Aligos Therapeutics — +36.85% on 2.18x volume

Aligos closed at $7.65 on 615,857 shares — 2.18x its 30-day average — with five-day momentum of +66.3%, extending a re-rating that began with its August 6 Q2 report: quarterly revenue of $27.8 million versus $1.0 million a year earlier on a $25 million China licensing deal, a net loss narrowed to $1.5 million ($0.14 per share from $1.53), and continued Phase 2 progress for pevifoscorvir sodium and ALG-170675 in chronic hepatitis B (GlobeNewswire — Aligos reports business progress and Q2 2026 financial results; TradingKey — Aligos Q2 2026: licensing revenue narrows the quarterly loss; QuiverQuant — Aligos reports $1.5M Q2 net loss and pipeline progress). The licensing line transformed a cash-burning clinical story into a revenue-diversified one overnight, and Monday’s session is the follow-through leg of that inflection rather than a fresh catalyst. Signal class: Class 2 single-stock fundamental (licensing-driven Q2), continuation leg.

TNON — Tenon Medical — +31.95% on 3.24x volume

Tenon Medical closed at $6.05 on 404,248 shares — 3.24x its 30-day average — on the first session after its 1-for-35 reverse stock split became effective at 12:01 a.m. ET on August 10 (RTTNews — Tenon Medical Implements 1-for-35 Reverse Stock Split; Nasdaq Trader — Equity Corporate Actions Alert #2026-554; Access Newswire — Tenon Medical announces 1:35 reverse stock split). Friday’s $0.13 close splits to a $4.55 reference price; the stock opened post-split and traded up to close 31.95% above that reference — a post-split bounce on above-average volume with five-day momentum of -9.0%. The Catamaran SI-joint fusion franchise received no fresh business news; the +32% is a mechanical repricing with a fresh post-split bid, the mirror image of Friday’s -22% pre-split slide on the same name. Signal class: Class 1 halt-release / reverse-split-adjacent (1-for-35 split, first post-split session).

IPHA — Innate Pharma — +28.32% on 27.19x volume

Innate Pharma closed at $2.22 on 6.8 million shares — 27.19x its 30-day average, the heaviest volume ratio on the entire board — with five-day momentum of +29.1%. Two catalysts landed the same morning: enrollment completed in the dose-escalation phase of the IPH4502 Phase 1 trial (76 advanced solid-tumor patients treated; early data show limited blood-related side effects and objective responses) (StocksToTrade — IPHA stock firms up as IPH4502 trial hits key milestone; Timothy Sykes — IPHA stock pops as IPH4502 trial hits key milestone), and the company said it will advance lacutamab toward Phase 3 following a partnership with Sobi, alongside appointing a new Chief Medical Officer (Innate Pharma IR — lacutamab Phase 3 advancement following Sobi partnership). The 27x volume on a +28% move is institutional confirmation of a pipeline-milestone read on the French natural-killer-cell oncology platform — the day’s cleanest fundamental winner. Signal class: Class 2 single-stock clinical event (IPH4502 Phase 1 milestone + lacutamab Phase 3 path).

Top 3 Losers — What Drove Them

SION — Sionna Therapeutics — -91.18% on 19.87x volume

Sionna collapsed to $4.50 on 38.6 million shares — 19.87x its 30-day average — from a $51.04 prior close, the worst session in the company’s history and a new record low (Barron’s — Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low). The trigger was a failed Phase 2a trial of its experimental cystic fibrosis drug; the company said it would stop developing the program as an addition to standard CF treatment, and the shares fell below the company’s reported gross cash position (Boston Business Journal — Sionna Therapeutics stock plunges 90% on failed CF drug trial; Reuters — Sionna scraps genetic disorder drug program after trial setback). The selloff drew same-day downgrades — BTIG to Neutral (MarketBeat) and Citizens JMP to Market Perform — and five-day momentum of -90.9% confirms the entire repricing is a Monday event: a wholesale unwind of the NBD1-stabilizer thesis in a single session. Signal class: Class 2 single-stock clinical failure (Phase 2a CF miss, program scrapped), new 52-week low.

TENX — Tenax Therapeutics — -89.77% on 17.11x volume

Tenax cratered to $1.38 on 65.5 million shares — 17.11x its 30-day average — from a $13.44 Friday close after topline results from the Phase 3 LEVEL trial of TNX-103 (oral levosimendan) in pulmonary hypertension with heart failure with preserved ejection fraction missed the primary endpoint of 6-minute walk distance and the key secondary patient-reported symptom scores (Reuters — Tenax heart drug fails to improve walking results in study, shares plunge; Tenax Therapeutics IR — topline results from Phase 3 LEVEL trial; CoinCentral — TENX drops 84% after Phase 3 LEVEL trial misses primary endpoint). The failure arrived after a run of analyst initiations and price targets as high as $50 ahead of the ESC presentation — the -90% session is a complete unwind of the LEVEL thesis, with 65.5 million shares changing hands (roughly the entire float) as the position exited in one day. Signal class: Class 2 single-stock clinical failure (Phase 3 LEVEL miss), new 52-week low.

QTRX — Quanterix — -39.95% on 6.78x volume

Quanterix fell to $2.42 on 4.05 million shares — 6.78x its 30-day average — with five-day momentum of -34.8%, after reporting Q2 results on the morning of August 10: revenue rose 34% year over year to $32.9 million but missed management’s expectations, and the company cut its 2026 revenue outlook as commercial challenges delayed its path to cash-flow breakeven (Yahoo Finance — Quanterix cuts 2026 revenue outlook as commercial challenges delay cash flow; Quanterix — financial results for Q2 2026; MarketBeat — QTRX Q2 2026 earnings report). The Simoa precision-biomarker platform converted a growth quarter into a guidance-cut repricing — revenue up a third, outlook down — the same forward-look asymmetry that has defined this earnings season, compounded by the morning’s announcement of a new Chief Commercial Officer as management tried to pair the bad news with a fresh hire. Signal class: Class 2 single-stock fundamental negative (Q2 miss + guidance cut).

The Cross-Cutting Pattern

Monday’s pattern is a two-sided clinical-currency day on a dead-flat tape: the market paid full price for pipeline milestones and licensing inflections on the upside, and exacted near-total destruction for failed data on the downside — with corporate-action mechanics and guidance asymmetry filling out the leaderboard. SION (-91.18%) and TENX (-89.77%) are the story: two mid-cap clinical stories, one Phase 2a miss that killed a program and one Phase 3 miss that killed a thesis, both unwound in a single session on 17-20x volume. The asymmetry is the durable signal — a +36.85% winner (ALGS) needed a $25 million licensing deal and a $27.8 million revenue quarter to print, while a failed endpoint routinely costs 90 cents on the dollar. The median of +0.04% with 570 directional names is the backdrop: when the tape has no direction, biotech’s remaining risk premium is priced almost entirely through binary clinical and guidance events.

The sector data confirms the defensive read. XLV (+1.67%) outpaced IBB (+1.17%) and XBI (+0.42%) while SPY sat flat — capital rotated into large-cap healthcare and out of the small-cap, event-driven end of the universe where Monday’s destruction happened. Devices — Implants (+4.80%, median +3.14%) was the only sector with a genuinely broad bid, and its median outperforming its average shows strength beyond TNON’s mechanical +32%. Drug Delivery/Formulation (-3.02%) and Small Molecule Pharma (-1.59%) lagged as the sectors housing the day’s big losers. And the stealth tape deserves one line: COCP’s 4.26x volume on +1.89% with 5d of +14.9% is the most accumulation-leaning unresolved signal on the board, while CVRX’s 3.27x on -0.84% with 5d of -56.9% shows last week’s -60% guidance crash still distributing.

The 5 Data Points That Matter

1. % change vs sector mean. The winners beat their sectors by wide margins — ALGS +36.85% against an RNA-adjacent tape at +1.83%, IPHA +28.32% against Antibodies at +1.39% — while the losers defined theirs: TENX sits in Drug Delivery/Formulation (-3.02% as a sector only because of it), and SION’s -91.18% is a company-specific destruction with no sector analog. Every print that mattered was idiosyncratic; sector averages mostly reflect the two crashes and the TNON bounce.

2. Volume ratio. The loser volume was historic: SION 19.87x on 38.6 million shares and TENX 17.11x on 65.5 million — the two heaviest prints on the board after IPHA’s 27.19x — meaning entire floats changed hands as positions exited. QTRX’s 6.78x confirms institutional selling on the guidance cut. On the winner side, IPHA’s 27.19x is the day’s defining institutional-confirmation number; ALGS’s 2.18x and TNON’s 3.24x are comparatively modest.

3. 5-day momentum. The crashes were pure Monday events — SION -90.9% and TENX -90.4% five-day momentum equal to their daily prints, with no pre-positioning. ALGS +66.3% against +36.85% daily shows the multi-day continuation nature of its run. QTRX -34.8% 5d shows its slide began before the report. TNON -9.0% 5d on a +31.95% day is the mechanical tell that the move is split mechanics, not business momentum.

4. 52-week range. SION closed at a record low; TENX closed at a record low; QTRX at $2.42 sits in the bottom decile of its range after a -40% repricing. ALGS at $7.65 has reclaimed mid-range territory after its licensing re-rating; IPHA at $2.22 is still in the lower half of its range despite the milestone; TNON’s post-split $6.05 is a new nominal reference with no comparable pre-split history. The two crash names are value-destroyed; the winners are re-ratings, not breakouts.

5. Cash / dilution context. SION closed below its reported gross cash — the market is now pricing liquidation, not pipeline. TENX faces a dead lead asset with no replacement. QTRX cut its outlook and delayed cash-flow breakeven — a growth story that now runs on borrowed time. On the upside, ALGS’s $25 million licensing deal and $27.8 million revenue quarter bought runway and credibility, and IPHA’s Sobi partnership funds a Phase 3 — capital infusions were the day’s best currency, exactly as they were on Friday.

What This Synthesis Will and Won’t Tell You

This synthesis is a one-day reading, and it should be read as such. It tells you what moved and why — the 108 anomaly-flagged names, the six data-defined top movers, the class of signal behind each, and the cross-cutting pattern: on a flat tape, biotech risk premium is now priced almost entirely through binary clinical, guidance, and capital-infusion events, with the downside tail (two -90% prints) far heavier than the upside. It does not tell you what happens next: SION can stabilize above cash or keep sliding toward a delisting path; TENX is a broken thesis with no obvious floor; QTRX’s cut needs quarters to prove out; ALGS’s licensing leg can extend or fade; TNON’s post-split bounce can hold or fill back to the reference.

The honest limits: the why-investigation covers the six data-defined top movers only — mid-board prints elsewhere in the top 15 (Heron Therapeutics -31.74% on 4.42x volume, 10x Genomics +12.57%, QuidelOrtho +11.93% in an oversold bounce after Friday’s -24.72%) carry their own stories that are noted but not deep-dived. Sector categories are broad, and small-n buckets (Nanotechnology, n=3; Generic Drugs, n=5) should be read with skepticism. And a single day’s median of +0.04% says nothing about the week or the quarter — the durable signal here is not any one print but the asymmetry it exposes: winners need licensing deals, milestones, and partnerships to move 30-40%, while a failed endpoint routinely destroys 90% of a company in one session. That is the risk profile of event-driven biotech, and Monday was its purest expression in weeks.

---

This is editorial analysis, not investment advice. Single-day returns reflect closing prices on 2026-08-10 and will change with market conditions, clinical readouts, financing terms, and regulatory events. Microcap and clinical-stage names can experience rapid reversals; readers should review the underlying disclosures before drawing conclusions about momentum durability.

Sources: Boston Business Journal on Sionna’s failed CF trial; Reuters on Sionna’s program scrap; Barron’s on Sionna’s record low; Reuters on Tenax’s LEVEL miss; Tenax Therapeutics IR on LEVEL topline results; Yahoo Finance on Quanterix’s guidance cut; Quanterix on Q2 2026 results; GlobeNewswire via Finviz on Aligos’ Q2; TradingKey on Aligos’ licensing revenue; StocksToTrade on IPHA’s IPH4502 milestone; Innate Pharma IR on lacutamab’s Phase 3 path; RTTNews on Tenon’s reverse split; Nasdaq Trader on TNON corporate action.